Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European expansions

This article was originally published in The Tan Sheet

Executive Summary

TSI Health Sciences' joined the growing number of North American dietary supplement firms boosting their presence in Europe by opening its first European-based sales and marketing office in Rochdale, Lancashire, UK June 14. Adrian Lindridge, formerly of the consumer products firm SSL International, has been appointed sales director for Europe. Sabinsa opened an office in Germany recently, citing an "increasingly tight regulatory environment in the EU." Similarly, San Clemente, Calif.-based Metagenics acquired Belgian manufacturer Biodynamics in early June, noting that "the evolving EU regulatory system will increase the opportunities for cross-border sales and shipments of our products throughout Europe." Recently approved regulations on fortified foods and health and nutrition claims are examples of the EU's developing regulatory system for supplements and functional foods (1"The Tan Sheet" May 22, 2006, p. 9)...

You may also be interested in...



EU Nutrition, Health Claim Reg Would Establish Approved-Claims Registry

Health claims referring to "children's development and health" will undergo a more stringent authorization process in the EU than other non-disease-risk-reduction claims, according to regulatory language adopted by the European Parliament May 16

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Topics

UsernamePublicRestriction

Register

PS099513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel